Eli Lilly And Stock Today
| LLY Stock | USD 778.62 0.38 0.05% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Eli Lilly is trading at 778.62 as of the 17th of December 2024; that is 0.05% down since the beginning of the trading day. The stock's open price was 779.0. Eli Lilly has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on December 6, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Eli Lilly's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of January 1978 | Category Healthcare | Classification Health Care |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 899.32 M outstanding shares of which 5.84 M shares are now shorted by investors with about 1.05 days to cover. More on Eli Lilly and
Moving together with Eli Stock
| 0.79 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Eli Stock
Eli Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Jacob Naarden | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Eli Lilly and Company, Eli Lilly and Company] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Institutional, SP 500 Index, SP 100 Index, SP 100, NYSE 100 Index, ARCA Pharmaceutical, Compulsion, Healthcare, ESG Investing, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEli Lilly can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eli Lilly's financial leverage. It provides some insight into what part of Eli Lilly's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eli Lilly and (LLY) is traded on New York Stock Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN, United States, 46285 and employs 43,000 people. Eli Lilly is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 700.57 B. Eli Lilly runs under Pharmaceuticals sector within Health Care industry. The entity has 899.32 M outstanding shares of which 5.84 M shares are now shorted by investors with about 1.05 days to cover.
Eli Lilly and has about 2.07 B in cash with 4.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Eli Lilly Probability Of Bankruptcy
Ownership AllocationEli Lilly holds a total of 899.32 Million outstanding shares. The majority of Eli Lilly and outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eli Lilly to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eli Lilly. Please pay attention to any change in the institutional holdings of Eli Lilly and as this could imply that something significant has changed or is about to change at the company. Please note that on December 6, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Eli Lilly's common stock.
Check Eli Ownership Details
Eli Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 14.6 M | |
| State Farm Mutual Automobile Ins Co | 2024-09-30 | 12.6 M | |
| International Assets Investment Management, Llc | 2024-09-30 | 12.5 M | |
| Norges Bank | 2024-06-30 | 11 M | |
| Wellington Management Company Llp | 2024-09-30 | 10.6 M | |
| Bank Of America Corp | 2024-09-30 | 10.2 M | |
| Capital Research Global Investors | 2024-09-30 | 9.3 M | |
| Northern Trust Corp | 2024-09-30 | 8.2 M | |
| Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 7.1 M | |
| Lilly Endowment Inc | 2024-09-30 | 96.9 M | |
| Vanguard Group Inc | 2024-09-30 | 73.8 M |
Eli Lilly Historical Income Statement
Eli Stock Against Markets
Eli Lilly Corporate Directors
| Kathi Seifert | Independent Director | Profile | |
| Jamere Jackson | Independent Director | Profile | |
| Juan Luciano | Lead Independent Director | Profile | |
| Gabrielle Sulzberger | Independent Director | Profile |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.